Register
Question 1
In PRRT planning, Ga-68 DOTATATE imaging guides decisions by indicating which of the following?
Correct Answer:
Presence and extent of somatostatin receptor expression, uptake intensity, lesion distribution; helps select patients likely to respond.
Explanation:
Ga-68 DOTATATE PET imaging reveals where somatostatin receptors are expressed, how strongly they are expressed (uptake intensity), and how the disease is distributed. This directly guides PRRT planning because the radiopharmaceuticals used in PRRT target those same receptors. If tumors show receptor expression and significant uptake, PRRT is more likely to accumulate in tumors and deliver effective radiation, making the patient a good candidate and helping plan the extent of treatment. Imaging also shows the overall lesion distribution, which informs which sites may require attention and helps in dose planning. In contrast, glucose metabolism imaging reflects metabolic activity and does not indicate receptor presence, so it doesn’t directly inform PRRT suitability. Evaluating lesions by size alone ignores the essential receptor biology that PRRT relies on, so it’s not sufficient for guiding therapy.
Question 2
Which brand names are associated with Y-90 microspheres?
Correct Answer:
Sir-Spheres and Thera-Spheres
Explanation:
The concept here is that Y-90 microspheres used for targeted liver therapy come under two well-known brand names: SIR-Spheres and TheraSphere. SIR-Spheres are resin-based microspheres, while TheraSphere are glass-based microspheres. Both are delivered via the hepatic artery to lodge in tumor vessels and deliver localized beta radiation, but they come from different manufacturers and have different physical forms. Zevalin, by contrast, is a Y-90 radiolabeled antibody used for lymphoma, not a microsphere, so it isn’t a brand name for Y-90 microspheres.
Question 3
I-131 mode of decay?
Correct Answer:
Beta negative and gamma
Explanation:
I-131 decays by beta minus emission to xenon-131, and the daughter nucleus emits gamma radiation as it de-excites. In this process, a neutron in I-131 converts to a proton, increasing the atomic number by 1 (Iodine, Z = 53, becomes Xenon, Z = 54) while the mass number stays at 131. The resulting xenon-131 is typically left in an excited state and releases a gamma photon to drop to a lower energy state, which is why gamma emission accompanies the beta particle. This combination—beta minus decay followed by gamma emission—is characteristic of I-131 and is what the answer reflects. Other decay modes, such as alpha decay, beta plus emission, or electron capture, do not describe this isotope’s typical decay path.
Question 4
Which of the following is NOT part of Sr-89 chloride normal biodistribution?
Correct Answer:
Liver
Explanation:
Sr-89 chloride behaves like calcium and concentrates in bone mineral, especially on surfaces where new bone is formed. Its normal biodistribution is largely skeletal, with uptake at bone surfaces tied to osteoblastic activity and only minimal soft-tissue involvement. It does not normally accumulate in the liver, so hepatic uptake would indicate an abnormal distribution. Therefore, the liver is not part of Sr-89 chloride’s normal biodistribution.
Question 5
For Ra-223 dichloride, which organ receives the highest radiation dose?
Correct Answer:
Bone surface
Explanation:
Ra-223 dichloride acts like calcium and localizes to bone, especially at sites of active bone formation (osteoblastic remodeling surfaces). Its emissions are alpha particles, which deposit a lot of energy over a very short distance. Because the radiopharmaceutical concentrates at the bone mineral at remodeling surfaces, the energy is deposited most intensely right at the bone surface where those cells are located. Other organs like the liver or kidney don’t accumulate Ra-223 to the same extent, and alpha particles don’t travel far enough to deliver comparable doses to deeper tissues. Some dose to nearby bone marrow can occur due to proximity, but the highest local dose remains at the bone surface where Ra-223 sits.
Question 1
Exam overview

About this Exam

Prepare with the Therapy Radiopharmaceuticals Practice Test practice quiz. This question bank includes 10 questions covering i-131, dose, y-90, microspheres, and highest. Use it to review important concepts, identify knowledge gaps, and build confidence for the related exam, course, or assessment.

More details

Additional Information

Therapy Radiopharmaceuticals Practice Test

This practice set contains 10 questions from the matching question bank and focuses on i-131, dose, y-90, microspheres, and highest. Work through each question carefully, review the provided solutions, and revisit topics that need more study before your next attempt.

This is an independent study resource intended for practice and review; it is not an official examination or an endorsement by any organization named in the title.

Quiz information

Frequently Asked Questions

The complete question count is available after full access is unlocked.
No fixed duration is currently configured for this quiz.
Question explanations are included where they are available in the quiz content, helping you review the reasoning after answering.
Yes. You can retake the practice test again as you continue studying during your available access period.
After your access is confirmed, you can continue into the complete practice exam from this quiz flow.
Unless explicitly stated otherwise, this page provides independent practice material for study and exam preparation and is not the official examination itself.
Keep studying

Related Questions

ABA Therapy New Hire Practice Exam

0 min

Chemotherapy Biotherapy Certification ONS Practice Testq

0 min

Chemotherapy and Radiation Therapy Practice Test

0 min

Choice Theory/Reality Therapy (CT/RT) Practice Exam

0 min

Aromatherapy Certification Practice Test

0 min

Art Therapy Credentials Board Exam (ATCBE) Practice Exam

0 min